References
- Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003;29:3–9.
- Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120:947–959.
- Jung T, Grune T. The proteasome and the degradation of oxidized proteins: part I-structure of proteasomes. Redox Biol. 2013;1:178–182.
- Schmidt M, Finley D. Regulation of proteasome activity in health and disease. Biochim Biophys Acta. 2014;1843:13–25.
- Paul S. Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches. Bioessays. 2008;30:1172–1184.
- Zheng Q, Huang T, Zhang L, et al. Dysregulation of ubiquitin-proteasome system in neurodegenerative diseases. Front Aging Neurosci. 2016;8:1–10.
- Egerer K, Kuckelkorn U, Rudolph PE, et al. Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol. 2002;29:2045–2052.
- Majetschak M, Perez M, Sorell LT, et al. Circulating 20S proteasome level in patients with mixed connective tissue disease and systemic lupus erythematosus. Clin Vaccine Immunol. 2008;15:1489–1493.
- Zoeger A, Blau M, Egerer K, et al. Circulating proteasomes are functional and have a subtype pattern distinct from 20S proteasomes in major blood cells. Clin Chem. 2006;52:2079–2086.
- Stoebner PE, Lavabre-Bertrand T, Henry L, et al. High plasma proteasome levels are detected in patients with metastatic malignant melanoma. Br J Dermatol. 2005;152:948–953.
- Salama HM, Abdel-Haleem H, Taha FM, et al. Plasma proteasome level as a potential marker for hepatocellular carcinoma. Arab J Gastroenterol. 2013;14:87–93.
- Heubner M, Wimberger P, Dahlmann B, et al. The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer. Gynecol Oncol. 2011;120:233–238.
- Martino M, Hoetzenecker K, Ankersmit HJ, et al. Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis. Br J Cancer. 2012;106:904–908.
- Dutaud D, Aubry L, Henry L, et al. Development and evaluation of a sandwich ELISA for quantification of the 20S proteasome in human plasma. J Immunol Methods. 2002;260:183–193.
- Bonella F, Sixt SU, Thomassen J, et al. Extracellular 20S proteasome in BAL and serum of patients with alveolar proteinosis. Immunobiology. 2015;220:382–388.
- Hempel D, Wojtukiewicz MZ, Kozlowski L, et al. Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors. Tumor Biol. 2011;32:753–759.
- Ma W, Kantarijan H, O’Brien S, et al. Enzymatic activity of circulating proteasome correlates with clinical behaviour in patients with chronic lymphocytic leukemia. Cancer. 2008;112:1306–1312.
- Ostrowska H, Hempel D, Holub M, et al. Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias. Clin Biochem. 2008;41:1377–1383.
- Lavabre-Bertrand T, Henry L, Carillo S, et al. Plasma proteasome level is a potential marker in patients with solid tumors and hemopoetic malignancies. Cancer. 2001;92:2493–2500.
- Ma W, Kantarijan H, Bekele B, et al. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res. 2009;15:3820–3826.
- Jakob C, Egerer K, Liebisch P, et al. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood. 2007;109:2100–2105.
- Oldziej A, Bolkun L, Galar M, et al. Assessment of proteasome concentration and chymotrypsin-like activity in plasma of patients with newly diagnosed multiple myeloma. Leuk Res. 2014;38:925–930.
- Allegra A, Alonci A, Gerace D, et al. New orally active proteasome inhibitors in multiple myeloma. Leuk Res. 2014;38:1–9.
- Muz B, Ghazarian RN, Ou M, et al. Spotlight on Ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther. 2016;10:217–226.
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548.
- Bradford MM. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye-binding. Anal Biochem. 1976;72:248–254.